NL-OMON41464已完成3 期
Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide. - FuTuRe
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Age 50 or older.
- •2. Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features.
- •3. Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone analogue or bilateral orchidectomy.
- •4. Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bone disease.
- •5. Metastatic disease documented by bone lesions on bone scan or by measurable soft tissue disease by CT
- •6. No prior cytotoxic chemotherapy for prostate cancer.
- •7. Asymptomatic or mildly symptomatic from prostate cancer
- •8. Written informed consent
排除标准
- •1. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
- •2. Known or suspected brain metastasis or active leptomeningeal disease.
- •3. History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer.
研究者
相似试验
Unknown
不适用
Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.Castration-resistant prostate cancerNL-OMON20629niversity Medical Center Groningen60
已完成
不适用
Evaluation of 18F-FDG-PET/CT in the diagnosis and treatment response of bone metastasis.bone metastasisJPRN-UMIN000005866ational Cancer Center Research Projects Management expenses Grants from the Government to National Cancer Research Center220
进行中（未招募）
不适用
Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.Castration-resistant prostate cancerEUCTR2012-005431-86-NLniversity Medical Center Groningen
已完成
Unknown
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancerJPRN-UMIN000053550iigata University Medical and Dental Hospital165
已完成
不适用
The Prognostic Value of 18F-FDG PET/CT Taken Immediately After Completion of Radiotherapy for Lung Cancer Treated with Concurrent Chemoradiotherapy: A Pilot Studyung cancerJPRN-UMIN000037493Juntendo University Faculty of Medicine19